

## STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA


Cat. No.: HY-148346A Molecular Formula:  $C_{48}H_{58}F_3N_{13}O_{14}$ Molecular Weight: 1098.05

Target: STING; Drug-Linker Conjugates for ADC

Immunology/Inflammation; Antibody-drug Conjugate/ADC Related Pathway:

Storage: 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (91.07 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.9107 mL	4.5535 mL	9.1071 mL
	5 mM	0.1821 mL	0.9107 mL	1.8214 mL
	10 mM	0.0911 mL	0.4554 mL	0.9107 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.28 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.28 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description

STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer<sup>[1]</sup>.

## **REFERENCES**

[1]. Jeremy R, et al. Antibody drug conjugates comprising sting agonists. Patent. WO2021202984A1.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com